Tags

Type your tag names separated by a space and hit enter

N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH.
Rheumatol Int. 2008 May; 28(7):657-60.RI

Abstract

Systemic sclerosis (SSc) is characterized by vascular dysfunction that may lead to pulmonary artery hypertension (PAH). The N-terminal pro-B type natriuretic peptide (NT-proNBP), a marker of cardiac failure, is a diagnostic marker of early PAH in patients with SSc without heart failure. Our aim was to determine whether NT-proBNP levels may be a useful tool to evaluate the response to bosentan therapy in patients with PAH secondary to SSc. Ten patients with symptomatic, severe PAH secondary to SSc, received bosentan, 62.5 mg twice a day for 4 weeks followed by 125 mg twice a day for 7 months. Ten patients with SSc without PAH served as controls for basal level of NT-proBNP. Blood samples were obtained before the beginning of the therapy and after 3 and 7 months of treatment. SSc patients with PAH had significantly higher serum levels of NT-proBNP than those without PAH, at baseline. After 3 and 7 months of therapy, NT-proBNP concentration showed a progressive decrease, nearly approaching statistical difference at 7 months when compared to baseline levels (P=0.953 and P=0.600). Our results show that serum NT-proBNP levels may be a useful marker for the response to bosentan therapy in patients with PAH secondary to SSc.

Authors+Show Affiliations

Department of Clinical and Experimental Medicine, Section of Internal Medicine, University of Verona, Policlinico GB Rossi, P.le LA Scuro 37134, Verona, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18092166

Citation

Simeoni, Sara, et al. "N-terminal pro-BNP in Sclerodermic Patients On Bosentan Therapy for PAH." Rheumatology International, vol. 28, no. 7, 2008, pp. 657-60.
Simeoni S, Lippi G, Puccetti A, et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int. 2008;28(7):657-60.
Simeoni, S., Lippi, G., Puccetti, A., Montagnana, M., Tinazzi, E., Prati, D., Corrocher, R., & Lunardi, C. (2008). N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatology International, 28(7), 657-60.
Simeoni S, et al. N-terminal pro-BNP in Sclerodermic Patients On Bosentan Therapy for PAH. Rheumatol Int. 2008;28(7):657-60. PubMed PMID: 18092166.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. AU - Simeoni,Sara, AU - Lippi,Giuseppe, AU - Puccetti,Antonio, AU - Montagnana,Martina, AU - Tinazzi,Elisa, AU - Prati,Daniele, AU - Corrocher,Roberto, AU - Lunardi,Claudio, Y1 - 2007/12/19/ PY - 2007/07/04/received PY - 2007/11/28/accepted PY - 2007/12/20/pubmed PY - 2008/7/25/medline PY - 2007/12/20/entrez SP - 657 EP - 60 JF - Rheumatology international JO - Rheumatol. Int. VL - 28 IS - 7 N2 - Systemic sclerosis (SSc) is characterized by vascular dysfunction that may lead to pulmonary artery hypertension (PAH). The N-terminal pro-B type natriuretic peptide (NT-proNBP), a marker of cardiac failure, is a diagnostic marker of early PAH in patients with SSc without heart failure. Our aim was to determine whether NT-proBNP levels may be a useful tool to evaluate the response to bosentan therapy in patients with PAH secondary to SSc. Ten patients with symptomatic, severe PAH secondary to SSc, received bosentan, 62.5 mg twice a day for 4 weeks followed by 125 mg twice a day for 7 months. Ten patients with SSc without PAH served as controls for basal level of NT-proBNP. Blood samples were obtained before the beginning of the therapy and after 3 and 7 months of treatment. SSc patients with PAH had significantly higher serum levels of NT-proBNP than those without PAH, at baseline. After 3 and 7 months of therapy, NT-proBNP concentration showed a progressive decrease, nearly approaching statistical difference at 7 months when compared to baseline levels (P=0.953 and P=0.600). Our results show that serum NT-proBNP levels may be a useful marker for the response to bosentan therapy in patients with PAH secondary to SSc. SN - 0172-8172 UR - https://www.unboundmedicine.com/medline/citation/18092166/N_terminal_pro_BNP_in_sclerodermic_patients_on_bosentan_therapy_for_PAH_ L2 - https://dx.doi.org/10.1007/s00296-007-0510-7 DB - PRIME DP - Unbound Medicine ER -